News and Trends 2 Nov 2017
German Biotech Pockets €18M in its Series A to Propel Autoimmune Disease Candidate Forward
Topas Therapeutics received an extra €4M from Boehringer Ingelheim Venture Fund to help its autoimmune disease candidates accelerated through trials. Hamburg-based Topas Therapeutics, a spin-off from Evotec, develops products for autoimmune diseases with high medical need. With the announcement of a €18M Series A, it hopes to take begin moving its candidates into the clinic. It had raised €14M thanks to investment from Epidarex […]